Boiron Enters Partnership with Panaxia Malta on Medical Cannabis
Boiron Laboratories has announced the signing of an agreement with Panaxia Malta, specializing in the research and development of medical cannabis. This partnership follows an operational collaboration within the framework of the French experiment conducted by the ANSM.
Boiron and Panaxia Malta have entered into a partnership that includes an option, exercisable from 2029, for Boiron to take a majority stake in the capital of Panaxia Malta. This option follows a successful collaboration in which Boiron handled the distribution of Panaxia's medications as part of the French experiment on assessing the relevance and feasibility of making medical cannabis available in France, conducted by the National Agency for the Safety of Medicines and Health Products (ANSM).
Financial Terms and Expansion Plans
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
The option is granted in exchange for a payment that could amount up to €3.2 million. According to Boiron, this option should allow Panaxia to continue its development in European countries where medical cannabis is authorized. Currently, 21 out of 27 countries within the European Union have already legislated in favor of its marketing.
Implications for the European Therapeutic Landscape
The partnership occurs in a therapeutic field that is becoming increasingly structured at the European level, where the regulatory framework for medical cannabis is progressively being established.
SectorSanté · Vaccins et laboratoires de recherche›Industrie Pharmaceutique
Context
Period
Period: 2025
Key reported figures
Revenue: 501106K€
Revenue growth: 2,8%
EBITDA: 71711K€
Net income: 32643K€
Dividend per share: 1.35€
Guidance from the release
Nous continuons à mettre toute notre énergie et notre détermination pour que chaque patient dans le monde puisse bénéficier de l'homéopathie et de nos autres solutions de santé.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
